Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00

Xilio Therapeutics (NASDAQ:XLO) had its price objective reduced by Raymond James from $6.00 to $4.00 in a research note issued to investors on Friday,Benzinga reports. Raymond James currently has an outperform rating on the stock.

Xilio Therapeutics Stock Performance

XLO stock opened at $1.09 on Friday. The stock has a market cap of $47.91 million, a P/E ratio of -0.63 and a beta of -0.24. The firm has a 50 day simple moving average of $0.88 and a 200 day simple moving average of $0.95. Xilio Therapeutics has a 52 week low of $0.49 and a 52 week high of $1.93.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xilio Therapeutics stock. Renaissance Technologies LLC increased its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 295,000 shares of the company’s stock after acquiring an additional 45,554 shares during the quarter. Renaissance Technologies LLC owned about 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent reporting period. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.